Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 3/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14826052 | 0.76 | DYRK1A (0.85) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL12850063 | 0.74 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL1355263 | 0.74 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL162566 | 0.74 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL19599268 | 0.74 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL1832813 | 0.74 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL921592 | 0.74 | KEAP1 (0.58) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL87222 | 0.74 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL21230274 | 0.74 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL3609207 | 0.74 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119080769-A | Method for preparing olprinone hydrochloride | 芜湖御草医药有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-114773341-A | Preparation method of olprinone hydrochloride | 河北爱尔海泰制药有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-111499631-B | Preparation method of olprinone hydrochloride key intermediate 1-imidazo [1,2-a ] pyridin-6-yl-2-acetone | 济南康桥医药科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-111499631-A | Preparation method of olprinone hydrochloride key intermediate | 山东美泰医药有限公司 | 2020-08-07 | — | — | CN | claimed |
| WO-2001074813-A2 | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| US-20260146037-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | SHANGHAI YIDIAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2026-05-28 | — | — | US | disclosed |
| CN-114401960-B | Glue degradation agent and using method thereof | NOVARTIS AG (CH) | 2026-05-26 | — | — | CN | disclosed |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | MyricX Pharma Limited (GB) | 2026-04-14 | — | — | US | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MYRICX PHARMA LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| EP-0644182-A1 | Cyclohexane derivatives useful as potassium channel openers | Eisai Co., Ltd. (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0609442-A1 | THIOFORMAMIDE DERIVATIVE | Eisai Co., Ltd. (JP) | 1994-08-10 | — | — | EP | disclosed |
| EP-0199127-B1 | 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative | Eisai Co., Ltd. (JP) | 1989-12-13 | — | — | EP | disclosed |
| US-4803276-A | CARDIOTONIC AGENTS, VASODILATION | EISAI CO., LTD. (JP) | 1989-02-07 | — | — | US | disclosed |
| US-4791203-A | CARDIOTONIC AGENTS | EISAI CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| US-4791202-A | CARDIOTONIC AGENTS; CONGESTIVE HEART FAILURE | EISAI CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| US-4751227-A | 3-cyano-5-(6-imidazo[1,2-a]pyridyl)pyridin-2-ols useful as cardiotonics | EISAI CO., LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0199127-A1 | 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative | Eisai Co., Ltd. (JP) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | DYRK1A 3517/4885KEAP1 1175/4885MEN1 3537/4885 |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | SLC7A1, FLT3, ABL1 | DYRK1A 480/4885KEAP1 3800/4885MEN1 127/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | DYRK1A 1279/4885KEAP1 3956/4885MEN1 1574/4885 |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | ABL1, FLT3, MTX2 | DYRK1A 465/4885KEAP1 4020/4885MEN1 92/4885 |
| US-20260146037-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | JAK1, CTSZ, CTSL | DYRK1A 1012/4885KEAP1 4093/4885MEN1 3993/4885 |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | DYRK1A 847/4885KEAP1 1396/4885MEN1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.